Literature DB >> 24054986

Epigenetic roles of MLL oncoproteins are dependent on NF-κB.

Hsu-Ping Kuo1, Zhong Wang, Dung-Fang Lee, Masayuki Iwasaki, Jesus Duque-Afonso, Stephen H K Wong, Chiou-Hong Lin, Maria E Figueroa, Jie Su, Ihor R Lemischka, Michael L Cleary.   

Abstract

MLL fusion proteins in leukemia induce aberrant transcriptional elongation and associated chromatin perturbations; however, the upstream signaling pathways and activators that recruit or retain MLL oncoproteins at initiated promoters are unknown. Through functional and comparative genomic studies, we identified an essential role for NF-κB signaling in MLL leukemia. Suppression of NF-κB led to robust antileukemia effects that phenocopied loss of functional MLL oncoprotein or associated epigenetic cofactors. The NF-κB subunit RELA occupies promoter regions of crucial MLL target genes and sustains the MLL-dependent leukemia stem cell program. IKK/NF-κB signaling is required for wild-type and fusion MLL protein retention and maintenance of associated histone modifications, providing a molecular rationale for enhanced efficacy in therapeutic targeting of this pathway in MLL leukemias.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24054986      PMCID: PMC3816582          DOI: 10.1016/j.ccr.2013.08.019

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  58 in total

1.  MLL fusion proteins preferentially regulate a subset of wild-type MLL target genes in the leukemic genome.

Authors:  Qian-Fei Wang; George Wu; Shuangli Mi; Fuhong He; Jun Wu; Jingfang Dong; Roger T Luo; Ryan Mattison; Joseph J Kaberlein; Shyam Prabhakar; Hongkai Ji; Michael J Thirman
Journal:  Blood       Date:  2011-04-25       Impact factor: 22.113

2.  Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia.

Authors:  Shujun Liu; Lai-Chu Wu; Jiuxia Pang; Ramasamy Santhanam; Sebastian Schwind; Yue-Zhong Wu; Christopher J Hickey; Jianhua Yu; Heiko Becker; Kati Maharry; Michael D Radmacher; Chenglong Li; Susan P Whitman; Anjali Mishra; Nicole Stauffer; Anna M Eiring; Roger Briesewitz; Robert A Baiocchi; Kenneth K Chan; Peter Paschka; Michael A Caligiuri; John C Byrd; Carlo M Croce; Clara D Bloomfield; Danilo Perrotti; Ramiro Garzon; Guido Marcucci
Journal:  Cancer Cell       Date:  2010-04-13       Impact factor: 31.743

3.  GSK-3 promotes conditional association of CREB and its coactivators with MEIS1 to facilitate HOX-mediated transcription and oncogenesis.

Authors:  Zhong Wang; Masayuki Iwasaki; Francesca Ficara; Chenwei Lin; Christina Matheny; Stephen H K Wong; Kevin S Smith; Michael L Cleary
Journal:  Cancer Cell       Date:  2010-06-15       Impact factor: 31.743

4.  Proteasome inhibitor PS-341 (bortezomib) induces calpain-dependent IkappaB(alpha) degradation.

Authors:  Chunyang Li; Shuzhen Chen; Ping Yue; Xingming Deng; Sagar Lonial; Fadlo R Khuri; Shi-Yong Sun
Journal:  J Biol Chem       Date:  2010-03-24       Impact factor: 5.157

5.  MLL-AF9-induced leukemogenesis requires coexpression of the wild-type Mll allele.

Authors:  Austin T Thiel; Peter Blessington; Tao Zou; Danielle Feather; Xinjiang Wu; Jizhou Yan; Hui Zhang; Zuguo Liu; Patricia Ernst; Gary A Koretzky; Xianxin Hua
Journal:  Cancer Cell       Date:  2010-02-17       Impact factor: 31.743

6.  AFF4, a component of the ELL/P-TEFb elongation complex and a shared subunit of MLL chimeras, can link transcription elongation to leukemia.

Authors:  Chengqi Lin; Edwin R Smith; Hidehisa Takahashi; Ka Chun Lai; Skylar Martin-Brown; Laurence Florens; Michael P Washburn; Joan W Conaway; Ronald C Conaway; Ali Shilatifard
Journal:  Mol Cell       Date:  2010-02-12       Impact factor: 17.970

Review 7.  Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives.

Authors:  D Chen; M Frezza; S Schmitt; J Kanwar; Q P Dou
Journal:  Curr Cancer Drug Targets       Date:  2011-03       Impact factor: 3.428

8.  DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia.

Authors:  Maria E Figueroa; Sanne Lugthart; Yushan Li; Claudia Erpelinck-Verschueren; Xutao Deng; Paul J Christos; Elizabeth Schifano; James Booth; Wim van Putten; Lucy Skrabanek; Fabien Campagne; Madhu Mazumdar; John M Greally; Peter J M Valk; Bob Löwenberg; Ruud Delwel; Ari Melnick
Journal:  Cancer Cell       Date:  2010-01-07       Impact factor: 31.743

9.  Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells.

Authors:  Teru Hideshima; Hiroshi Ikeda; Dharminder Chauhan; Yutaka Okawa; Noopur Raje; Klaus Podar; Constantine Mitsiades; Nikhil C Munshi; Paul G Richardson; Ruben D Carrasco; Kenneth C Anderson
Journal:  Blood       Date:  2009-05-12       Impact factor: 22.113

10.  A Myc network accounts for similarities between embryonic stem and cancer cell transcription programs.

Authors:  Jonghwan Kim; Andrew J Woo; Jianlin Chu; Jonathan W Snow; Yuko Fujiwara; Chul Geun Kim; Alan B Cantor; Stuart H Orkin
Journal:  Cell       Date:  2010-10-15       Impact factor: 41.582

View more
  49 in total

1.  NF-κB activation impairs somatic cell reprogramming in ageing.

Authors:  Clara Soria-Valles; Fernando G Osorio; Ana Gutiérrez-Fernández; Alejandro De Los Angeles; Clara Bueno; Pablo Menéndez; José I Martín-Subero; George Q Daley; José M P Freije; Carlos López-Otín
Journal:  Nat Cell Biol       Date:  2015-07-27       Impact factor: 28.824

2.  HBV X Protein induces overexpression of HERV-W env through NF-κB in HepG2 cells.

Authors:  Cong Liu; Lijuan Liu; Xiuling Wang; Youyi Liu; Miao Wang; Fan Zhu
Journal:  Virus Genes       Date:  2017-06-20       Impact factor: 2.332

3.  Musashi2 sustains the mixed-lineage leukemia-driven stem cell regulatory program.

Authors:  Sun-Mi Park; Mithat Gönen; Ly Vu; Gerard Minuesa; Patrick Tivnan; Trevor S Barlowe; James Taggart; Yuheng Lu; Raquel P Deering; Nir Hacohen; Maria E Figueroa; Elisabeth Paietta; Hugo F Fernandez; Martin S Tallman; Ari Melnick; Ross Levine; Christina Leslie; Christopher J Lengner; Michael G Kharas
Journal:  J Clin Invest       Date:  2015-02-09       Impact factor: 14.808

4.  Curcumin effectively inhibits oncogenic NF-κB signaling and restrains stemness features in liver cancer.

Authors:  Jens U Marquardt; Luis Gomez-Quiroz; Lucrecia O Arreguin Camacho; Federico Pinna; Yun-Han Lee; Mitsuteru Kitade; Mayrel Palestino Domínguez; Darko Castven; Kai Breuhahn; Elizabeth A Conner; Peter R Galle; Jesper B Andersen; Valentina M Factor; Snorri S Thorgeirsson
Journal:  J Hepatol       Date:  2015-05-01       Impact factor: 25.083

Review 5.  Two decades of leukemia oncoprotein epistasis: the MLL1 paradigm for epigenetic deregulation in leukemia.

Authors:  Bin E Li; Patricia Ernst
Journal:  Exp Hematol       Date:  2014-09-28       Impact factor: 3.084

6.  IBRUTinib: BRUTe force against bortezomib-resistant myeloma cells.

Authors:  Lingling Xian; Carol Ann Huff; Linda M S Resar
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

7.  Therapeutic Targeting of MLL Degradation Pathways in MLL-Rearranged Leukemia.

Authors:  Kaiwei Liang; Andrew G Volk; Jeffrey S Haug; Stacy A Marshall; Ashley R Woodfin; Elizabeth T Bartom; Joshua M Gilmore; Laurence Florens; Michael P Washburn; Kelly D Sullivan; Joaquin M Espinosa; Joseph Cannova; Jiwang Zhang; Edwin R Smith; John D Crispino; Ali Shilatifard
Journal:  Cell       Date:  2017-01-05       Impact factor: 41.582

8.  CBP Modulates Sensitivity to Dasatinib in Pre-BCR+ Acute Lymphoblastic Leukemia.

Authors:  Jesús Duque-Afonso; Chiou-Hong Lin; Kyuho Han; David W Morgens; Edwin E Jeng; Ziming Weng; Johan Jeong; Stephen Hon Kit Wong; Li Zhu; Michael C Wei; Hee-Don Chae; Martin Schrappe; Gunnar Cario; Justus Duyster; Xiangshu Xiao; Kathleen M Sakamoto; Michael C Bassik; Michael L Cleary
Journal:  Cancer Res       Date:  2018-09-27       Impact factor: 12.701

9.  E2A-PBX1 Remodels Oncogenic Signaling Networks in B-cell Precursor Acute Lymphoid Leukemia.

Authors:  Jesús Duque-Afonso; Chiou-Hong Lin; Kyuho Han; Michael C Wei; Jue Feng; Jason H Kurzer; Corina Schneidawind; Stephen Hon-Kit Wong; Michael C Bassik; Michael L Cleary
Journal:  Cancer Res       Date:  2016-10-07       Impact factor: 12.701

Review 10.  Role of dendritic cell-pathogen interactions in the immune response to pulmonary cryptococcal infection.

Authors:  Alison J Eastman; John J Osterholzer; Michal A Olszewski
Journal:  Future Microbiol       Date:  2015       Impact factor: 3.165

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.